NeuroEndocrine tumor therapy with lutetium-177-octreotate and everolimus (NETTLE): A Phase I study

Cancer Biotherapy and Radiopharmaceuticals

Volumn 30, Issue 6, 2015, Pages 261-269

  Claringbold, Phillip G ^a   Turner, J Harvey ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

molecular therapy NET; PRRT; targeted radionuclide biological therapy

Indexed keywords

EVEROLIMUS; LUTETIUM 177; OCTREOTATE LU 177; RADIOISOTOPE; UNCLASSIFIED DRUG; LUTETIUM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CREATININE CLEARANCE; DRUG DOSE ESCALATION; FEMALE; FOLLOW UP; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MOLECULARLY TARGETED THERAPY; NEPHROTOXICITY; NEUTROPENIA; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; CLINICAL TRIAL; MIDDLE AGED; NEUROENDOCRINE TUMORS; PATHOLOGY; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; EVEROLIMUS; FEMALE; HUMANS; LUTETIUM; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; TREATMENT OUTCOME;

EID: 84937218776     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2015.1876     Document Type: Article

References (21)

1. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005; 23: 2754
2. Jensen RT, Cadiot G. Brandi ML, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: Functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012; 95: 98
3. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol. 2008; 26: 2124
4. Jan H, Wyld D, Burge M. ENETS 12th Annual Conference Proc 2015 Abst N3
5. Ezziddin S, Attassi M, Yong-Hing CJ, et al. Predictors of long-Term outcome in patients with well differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014; 55: 183
6. Claringbold PG, Brayshaw PA, Price RA, et al. Phase II study of radiopeptide 177Lutetium-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2011; 38: 302
7. Claringbold PG, Price RA, Turner JH. Phase I-II study of radiopeptide 177Lu-octreotate in combinationwith capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm. 2012; 27: 561
8. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-Acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomized placebo-controlled, phase 3 study. Lancet. 2011; 378: 2005
9. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 514
10. Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 501
11. Giaccia AJ. Molecular radiobiology: The state of the art. J Clin Oncol. 2014; 32: 2871
12. Morris ZS, Harari P. Interaction of radiation therapy with molecular targeted agents. J Clin Oncol. 2014; 32: 2886
13. De Decker M, Turner JH. Automatedmodule radiolabeling of peptides and antibodies with Gallium-68, and Lutetium-177 and Iodine-131. Cancer Biother Radiopharm. 2012; 27: 72
14. Calais PJ, Turner JH. Radiation safety of outpatient 177Luoctreotate radiopeptide therapy of neuroendocrine tumors. Ann Nucl Med. 2014; 28: 531
15. Dash A, Chakraborty S, Raghavan M, et al. Peptide receptor radionuclide therapy: An overview. Cancer Biother Radiopharm. 2015; 30: 47
16. Kesavan M, Claringbold PG, Turner JH. Hematological toxicity of combined lutetium-177-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors followed longterm. Neuroendocrinology. 2014; 99: 108
17. Woodcock J, Griffin JP, Behrman RE. Development of novel combination therapies. N Engl J Med. 2011; 364: 11
18. Kulke MH, Ruszniewski P, Van Cutsem E, et al A randomized open-label Phase II study of everolimus alone or in combination with pasireotide LAR in advanced progressive pancreatic neuroendocrine tumors (pNET): COOPERATIVE-2 Trial ENETS 12th Annual Conference Proc 2015 Abst L10
19. Pool SE, Bison S, Koelewijn SJ, et al. mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer. Cancer Res. 2013; 73: 12
20. Bison S, Pool SE, Koelewijn SJ, et al. Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0, Tyr3] octreotate in combination with RAD001 treatment: Further investigation on tumor metastasis and response in the rat pancreatic CA20948 tumor model. EJNMMI Res. 2014; 4: 21
21. Weber JS, Levit LA, Adamson PC, et al. ASCO Policy statement update: The critical role of phase I trials in cancer research and treatment. J Clin Oncol. 2015; 33: 278